Osteonecrosis of the jaws and bisphosphonates

Current Osteoporosis Reports

Volumn 6, Issue 1, 2008, Pages 31-38

  Pendrys, David G ^a   Silverman, Stuart L ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; INCADRONIC ACID; MINODRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DISEASE SURVEILLANCE; DRUG MEGADOSE; HUMAN; HYPOTHESIS; JAW OSTEONECROSIS; MEDICAL RECORD REVIEW; METABOLIC BONE DISEASE; MULTIPLE MYELOMA; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREVALENCE; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; THYROID CANCER; BONE NECROSIS; BONE TUMOR; CHEMICALLY INDUCED DISORDER; JAW DISEASE;

BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS; OSTEOPOROSIS; PREVALENCE; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS;

EID: 44849118220     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-008-0006-8     Document Type: Review

References (47)

1. Marx R: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003, 61:1115-1118.
2. Ruggiero S, Mehrotra B, Rosenberg T, Engroff S: Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534.
3. Migliorati C, Casiglia J, Epstein J, et al.: Managing the care of patients with bisphosphonate-associated osteonecrosis. J Am Dent Assoc 2005, 136:1658-1668.
4. American Dental Association Council on Scientific Affairs: Dental management of patients receiving oral bisphosphonate therapy. Expert panel recommendations. J Am Dent Assoc 2006, 137:1144-1150.
5. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons Position paper on Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 2007, 65: 369-376.
6. Mavrokokki T, Cheng A, Stein B, Goss A: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007, 65:415-423.
7. Polizzotto M, Cousins V, Schwarer A: Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 2005, 132:114-117.
8. ASBMR Task Force on Bisphosphonate-associated ONJ: Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
9. Schwartz H: OsteonecrAsis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 1982, 4:252-253.
10. Sung E, Chan S, Sakurai K, et al.: Osteonecrosis of the maxilla as a complication to chemotherapy: A case report. Spec Care Dentist 2002, 22:142-146.
11. Lenz JH, Steiner-Kramer B, Schmidt W, et al.: Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg 2005, 33:395-403.
12. Marx R, Fortin M, Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005, 63:1567-1575.
13. Woo SB, HellsBein J, Kalmer J: Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-761.
14. Carter GD, Goss AN: Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003, 48:268.
15. Durie BGM, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates [letter]. N Engl J Med 2005, 353:99.
16. Shane E, Goldring S, Christakos S, et al.: Osteonecrosis of the jaw: more research needed [editorial]. J Bone Miner Res 2006, 21:1503-1505.
17. Sambrook P, Olver I, Goss A: Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006, 35:801-803.
18. Black DM, Delmas PD, Eastell R, for the HORIZON-Pivotal Fracture Trial Group: Once-yearly zoledronic acid 5 mg for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
19. Hoff AO, Toth B, Altundag K, et al.: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy [abstract]. J Bone Miner Res 2005, 20(Suppl 1):S55.
20. Murad O, Arora S, Farag A, Guber H: Bisphosphonates and osteonecrosis of the jaw: A retrospective study. ENDO 2006, P2-500.
21. Felsenberg D, Hoffmeister B, Amling M, et al.: Kiefernekrosen nach hoch dosierter bisphosphonattherapie. Dtsch Arztebl 2006, 103:3078-3081.
22. Melo M, Obeid G: Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 2005, 71:111-113.
23. Badros A, Weikel D, Salama A, et al.: Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006, 24:945-952.
24. Farrugia M, Summerlin DJ, Krowiak E, et al.: Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006, 116:115-120.
25. Dimitrakopoulos I, Magopoulos C, Karakasis D: Bisphosphonate-induced avascular osteonecrosis of the jaws: A clinical report of 11 cases. Int J Oral Maxillofac Surg 2006, 35:588-593.
26. Bagan J, Jimenez Y, Murillo J, et al.: Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2005, 42:327-329.
27. Dunstan CR,TFelsenberg D, Seibel MJ: Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2006, 4:42-55.
28. Shimura K, Shimazaki C, Taniguchi K, et al.: Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 2006, 84:343-345.
29. Montazeri AH, Erskine JG, McQuaker IG: Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 2007, 79:69-77.
30. Li J, Mashiba T, Burr DB: Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001, 69:281-286.
31. Komatsubara S, Mori S, Mashiba T, et al.: Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004, 19:999-1005.
32. Mashiba T, Turner CH, Hirano T, et al.: Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524-531.
33. Mashiba T, Mori S, Burr DB, et al.: The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005, 23(Suppl):36-42.
34. Hirano T, Turner CH, Forwood MR, et al.: Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone 2000, 27:13-20.
35. Allen MR, Iwata K, Phipps R, Burr DB: Risedronate and alendronate similarly suppress remodeling and increase microdamage in beagles after 1 year of treatment at clinical doses. J Bone Miner Res 2005, 20(Suppl 1):1081.
36. Chapurlat RD, Arlot M, Burt-Pichat B, et al.: Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long term bisphosphonates: A bone biopsy study. J Bone Miner Res 2007, 22:1502-1509.
37. Odvina CV, Zerwekh JE, Rao DS, et al.: Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
38. Lenart B, Neviaser A, Peterson MG, et al.: Low energy femoral diaphyseal fractures in patients on alendronate. J Bone Miner Res 2007, 22(Suppl 1):S430.
39. Hansen T, Kunkel M, Weber A, James Kirkpatrick C: Osteonecrosis of the jaws in patients treated with bisphosphonates: Histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006, 35:155-160.
40. Novartis expert panel. London, UK; February 13, 2006.
41. Fournier P, Boissier S, Filleur S, et al.: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538.
42. Wood J, Bonjean K, Ruetz S, et al.: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
43. Ruggiero SL, Gralow J, Marx RE, et al.: Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006, 2:7-14.
44. Kenzora J, Glimcher T: Accumulative cell stress: the multifactorial etiology of idiopathic osteonecrosis. Orthop Clin North Am 1985, 16:669-679.
45. Fleisch H: Bisphosphonates in Bone Disease. From the Laboratory to the Patient. San Diego, CA: Academic Press; 2000.
46. Coleman RE: Bisphosphonates in breast cancer. Ann Oncol 2005, 16:687-695.
47. US Department of Health and Human Services: Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.